Affiliation:
1. Affiliated Cancer Hospital & Institute of Guangzhou Medical University
2. Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University
3. Zhujiang Hospital, Southern Medical University
4. The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital
5. Zhaoqing Medical College
Abstract
Abstract
Purpose
LncRNA-BF368575 is a novel long non-coding RNA, its biological function in hepatocellular carcinoma (HCC) remains unknown.
Methods
The expression levels of lncRNA-BF368575 in HCC tissues and cell lines were evaluated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). In situ hybridization (ISH) was performed to determine the expression of lncRNA-BF368575 in a tissue chip containing 89 paired HCC and para-cancerous tissues. Fractionation of nuclear and cytoplasmic RNA was performed to determine the subcellular localization of lncRNA-BF368575. Cell viability and colony-forming ability were determined by cell counting kit-8 (CCK-8) assay and colony formation assay. Tumor growth in vivo was detected using the xenograft model. The molecular mechanisms of lncRNA-BF368575 were investigated using Western blotting and RNA-Binding Protein Immunoprecipitation (RIP).
Results
The results showed that lncRNA-BF368575 was increased in most HCC tissues and cell lines. Moreover, the lower lncRNA-BF368575 expression level is a favorable prognostic factor in disease-free survival (DFS). LncRNA-BF368575 is mostly localized in the cytoplasm. In vitro and in vivo experiments showed that downregulation of lncRNA-BF368575 suppressed cell proliferation and colony-forming activity, yet overexpression of lncRNA-BF368575 leads to an opposite result. Furthermore, lncRNA-BF368575 activates the PI3K/AKT/mTOR signaling pathway by increasing the expression of p-PI3K(Tyr607), p-AKT(Thr308), p-mTOR(Ser2448), p-4E-BP1(Thr37/46), p-S6(Ser235/236). LY294002 could reverse the biological functions of lncRNA-BF368575. RIP shows that LncRNA-BF368575 could bind to p-mTOR(Ser2448), p-AKT(Thr308), and p-4E-BP1(Thr37/46).
Conclusion
Our study demonstrates that lncRNA-BF368575 enhances HCC proliferation and growth both in vitro and vivo via activating the PI3K/AKT/mTOR signaling pathway, which implicates that our findings may provide a potential target for HCC treatments.
Publisher
Research Square Platform LLC